Rep. April McClain Delaney Sells Shares of STERIS plc (NYSE:STE)

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 29th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

STERIS Stock Performance

Shares of NYSE:STE opened at $233.17 on Wednesday. The business has a fifty day moving average of $213.64 and a 200-day moving average of $225.91. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The firm has a market cap of $22.72 billion, a PE ratio of 29.40 and a beta of 0.91.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter last year, the company earned $2.74 EPS. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, equities research analysts predict that STERIS plc will post 11.17 EPS for the current fiscal year.

STERIS Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Friday, September 4th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a dividend yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date is Friday, September 4th. STERIS’s dividend payout ratio is 31.78%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STE. Piper Sandler reiterated an “overweight” rating and set a $270.00 target price on shares of STERIS in a research report on Thursday, May 21st. UBS Group started coverage on shares of STERIS in a research report on Tuesday, July 28th. They issued a “buy” rating and a $275.00 price objective for the company. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. KeyCorp decreased their price objective on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Finally, Wall Street Zen cut STERIS from a “buy” rating to a “hold” rating in a research note on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $277.25.

Hedge Funds Weigh In On STERIS

Several large investors have recently bought and sold shares of STE. Generali Investments Management Co LLC acquired a new stake in STERIS during the 2nd quarter worth $262,000. Fulton Bank N.A. boosted its position in shares of STERIS by 10.4% in the 2nd quarter. Fulton Bank N.A. now owns 2,881 shares of the medical equipment provider’s stock worth $607,000 after purchasing an additional 272 shares during the last quarter. Elevation Wealth Partners LLC boosted its position in shares of STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 113 shares during the last quarter. Czech National Bank grew its stake in shares of STERIS by 4.5% during the second quarter. Czech National Bank now owns 27,916 shares of the medical equipment provider’s stock worth $5,878,000 after purchasing an additional 1,206 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of STERIS by 56.5% during the second quarter. Assenagon Asset Management S.A. now owns 76,440 shares of the medical equipment provider’s stock worth $16,096,000 after purchasing an additional 27,594 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at STERIS

In other news, VP John Adam Zangerle sold 1,419 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the completion of the sale, the vice president directly owned 35,259 shares of the company’s stock, valued at $7,379,003.52. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel A. Carestio sold 3,054 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total transaction of $655,510.56. Following the completion of the sale, the chief executive officer owned 65,021 shares in the company, valued at $13,956,107.44. This represents a 4.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 7,328 shares of company stock valued at $1,554,051. 1.12% of the stock is currently owned by company insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.